Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
NEOVACS logo — Nous développons les thérapies de demain et investissons dan...

NEOVACS

Nous développons les thérapies de demain et investissons dans des sociétés innovantes en Biotech et Medtech

Founded 1993 France France 18 employees Post-IPO Equity Total: $37.95M Biotechnology, Health Care +2

General Information

Company Name NEOVACS
Founded Year 1993
Location France France
Employees 18
Industries Biotechnology, Health Care, Health and Wellness +1
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with NEOVACS. To contact NEOVACS, visit neovacs.fr.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does NEOVACS compare?

A PDF of NEOVACS and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting NEOVACS soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About NEOVACS

**NEOVACS**

NEOVACS is a French Biotechnology company founded in 1993. Their mission is to develop therapeutic vaccines for the treatment of autoimmune and inflammatory diseases. Additionally, they invest in innovative companies within the Biotech and Medtech industries. Their headquarters are based in France.

The most recent investment in NEOVACS was a €1.20M post-IPO equity investment on 05 May 2025. The details of the investing party are not stated.

NEOVACS presents an interesting prospect for venture capitalists looking to invest in the biotech and medtech sectors. With a strong focus on therapeutic vaccines and a track record of investment in innovative companies, they are positioned as a promising player in the health and wellness industry.

Business keywords: Therapeutic Vaccines, Autoimmune Diseases, Inflammatory Diseases, Immunotherapy, Medtech, AIDS Treatment, Cancer Treatment, Polyclonal Antibody Response, Immunologist, Viral Proteins, Monoclonal Antibodies, Cytokine-related Diseases, Allergic Diseases

Services & Products

biotechnology research and development
drug development
investing in biotech and medtech companies

Target Customers

patients with lupus and allergies biotech and medtech companies

Funding Rounds & Investors (9)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity €1.20M -
05 May 2025
Post IPO Equity €250.00K -
22 Jan 2025
Post IPO Debt €4.00M -
22 Jun 2021
Post IPO Debt €1.00M 1
Alpha Blue Ocean
Alpha Blue Ocean
08 Feb 2021
Post IPO Equity €6.00M -
31 Jul 2017
Post IPO Equity €5.00M 1
Bpifrance
Bpifrance
06 Jan 2016
Post IPO Equity €7.50M -
29 Jun 2015
Venture Round €13.00M 2
Novartis Venture Fund Truffle Capital
Novartis Venture Fund, Truffle Capital
17 Jul 2007
Venture Round Undisclosed 1
Debiopharm Innovation Fund
Debiopharm Innovation Fund
27 Jun 2005

NEOVACS Alternatives & Competitors

View All Alternatives
NEOVACS vs
Tridek-One
Tridek-One France

We develop first-in-class CD31 checkpoint agonists for the treatment of auto-immune diseases

Venture round
12 employees
Biotechnology, Health Care
NEOVACS vs
Novelogics Biotechnology Inc.
Novelogics Biotechnology Inc. Canada

Pre-clinical stage biotech company developing an antibody immunotherapy drug for cancer using an “In...

Angel
1 employees
Biotechnology, Health Care
NEOVACS vs
Antharis Therapeutics, Inc.
Antharis Therapeutics, Inc. United States

Antharis Therapeutics is a multinational biopharmaceutical company developing new, cutting-edge trea...

18 employees
Biopharma, Biotechnology
View all alternatives

FAQ About NEOVACS

Nous développons les thérapies de demain et investissons dans des sociétés innovantes en Biotech et Medtech
NEOVACS was founded in 1993.
NEOVACS is headquartered in France.
NEOVACS operates in Biotechnology, Health Care, Health and Wellness and Medical Devices. Its work centres on Therapeutic Vaccines, Autoimmune Diseases, Inflammatory Diseases and Immunotherapy. Its customers include patients with lupus and allergies and biotech and medtech companies.
NEOVACS has approximately 18 employees.
NEOVACS has completed 9 funding rounds, raising a total of $37.95M. The latest funding stage is Post-IPO Equity.
NEOVACS offers: biotechnology research and development, drug development, investing in biotech and medtech companies.
Top alternatives and competitors to NEOVACS include Tridek-One, Novelogics Biotechnology Inc., Antharis Therapeutics, Inc., MabGenesis Inc., Evelo Biosciences. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
NEOVACS and Tridek-One are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for NEOVACS, https://bouncewatch.com/company/neovacs, updated 7 June 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes